Claß, S.
von Wrede, R.
Baumgartner, T.
Surges, R.
Article History
Accepted: 21 August 2023
First Online: 6 October 2023
Declarations
:
: S. Claß declares that she has no competing interests. Memberships and advisory activities of R. von Wrede: memberships: DGfE, DGKN; advisory or speaker activities: Angelini, Arvelle, Apocare, Bial, Desitin, Eisai, JAZZ pharmaceuticals, UCB Pharma. Memberships and advisory activities of T. Baumgartner: memberships: DGN, DGfE, DGKN; advisory or speaker activities: Eisai, UCB Pharma. Memberships and advisory activities of R. Surges: memberships: AES, DGN, DGfE, DHV, DGKN, AG Epilepsiechirurgie; advisory or speaker activities: Angelini, Arvelle, Bial, Desitin, Eisai, Janssen-Cilag GmbH, Livanova, Novartis, Precisis GmbH, UNEEG, UCB Pharma, Zogenix.
: The Ethics Commission for Clinical Trials on Humans and Epidemiological Research with Personal Data of the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn has confirmed that there are no professional ethical or professional legal concerns to be raised for the project described here (reference number 082/23). The creation and integration of the digital learning tools were not planned as a prospective trial, but were part of the department’s implementation to support the clinical teaching. Thus, informed consent was not obtained from the students.
: The supplement containing this article is not sponsored by industry.